CASI PHARMACEUTICALS INC (CASI) Stock Income Statement
NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 31.37M | 28.54M | 33.88M | 43.11M | 30.17M | |||
| Minority Interest Expense | N/A | 0.00 | 2.60M | 8.74M | 700.00K | |||
| Cost Of Goods | 13.61M | 12.59M | 13.83M | 15.83M | 12.56M | |||
| Gross Profit | 17.76M | 15.95M | 20.05M | 27.28M | 17.61M | |||
| Operating Expenses | 53.19M | 50.36M | 45.33M | 53.77M | 52.89M | |||
| Research and Development | 8.38M | 8.90M | 9.86M | 16.00M | 14.42M | |||
| Selling, General, and Administrative Expenses | 44.81M | 41.44M | 41.84M | 37.77M | 38.47M | |||
| Operating Income | -35.43M | -34.41M | -25.28M | -26.49M | -35.28M | |||
| Interest Income/Expense | 1.10M | 1.17M | 233.00K | -202.00K | 6.30M | |||
| Other Income/Expense | 48.00K | 188.00K | 764.00K | 44.00K | 558.00K | |||
| Non Recurring Items | N/A | -5.02M | -2.01M | -10.78M | -7.42M | |||
| Income Before Taxes | -39.29M | -38.07M | -26.29M | -37.43M | -35.84M | |||
| Income Tax | N/A | 0.00 | -81.00K | 1.98M | 0.00 | |||
| Net Income | -40.48M | -39.26M | -26.96M | -41.01M | -36.65M | |||
| EBITDA | N/A | -32.08M | -21.54M | -24.07M | -33.47M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.51 | -2.56 | -2.02 | -3.01 | -2.69 | |||
| Non GAAP EPS | N/A | N/A | -2.02 | -3.40 | -2.70 | |||
| Statistics | ||||||||
| Gross Profit Margin | 56.62% | 55.88% | 59.19% | 63.28% | 58.38% | |||
| Profit Margin | -129.05% | -137.57% | -79.58% | -95.14% | -121.50% | |||
| Operating Profit Margin | -112.94% | -120.59% | -74.62% | -61.45% | -116.95% | |||
All data in USD